New drug cocktail plus radiation shows promise against esophageal cancer
NCT ID NCT00213486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a combination of two chemotherapy drugs, cisplatin and irinotecan, given weekly along with radiation therapy for patients with locally advanced esophageal cancer. The study enrolled 43 participants and aimed to see how many had no detectable tumor after treatment. Researchers also tracked side effects and survival rates at one and two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cisplatin and irinotecan (chemotherapy drugs)
What this could lead to
If successful, this could provide an alternative chemoradiotherapy regimen for patients with locally advanced esophageal cancer, potentially improving tumor clearance and survival.
What could go wrong
This is a small, early-phase (Phase II) trial with only 43 participants. The results may not apply to all patients, and the combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Rouen
Rouen, 76031, France